BMY

57.13

0.40% 0.23

Dopo l'orario di chiusura: 57.13

Bristol Myers Squibb Co (BMY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BMY Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$56.90

Aprire:

$57.45

Volume 24 ore:

7.83M

Relative Volume:

0.70

Capitalizzazione di mercato:

$116.66B

Reddito:

$48.48B

Utile/perdita netta:

$7.27B

Rapporto P/E:

16.04

EPS:

3.5626

Flusso di cassa netto:

$11.91B

1 W Prestazione:

-0.24%

1M Prestazione:

+1.20%

6M Prestazione:

+9.01%

1 anno Prestazione:

+12.70%

Intervallo 1D:

$56.77

$57.60

Intervallo di 1 settimana:

$55.26

$57.60

Portata 52W:

$42.52

$62.89

Bristol Myers Squibb Co Stock (BMY) Company Profile

Nome

Bristol Myers Squibb Co

Settore

Healthcare (1109)

Industria

Drug Manufacturers - General (20)

Telefono

(609) 252-4621

Indirizzo

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

Dipendente

32,500

Cinguettio

@BMSNEWS

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

BMY's Discussions on Twitter

Compare BMY vs LLY, JNJ, ABBV, MRK, NVS

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BMY Bristol Myers Squibb Co	57.13	116.19B	48.48B	7.27B	11.91B	3.5626
LLY Lilly Eli Co	1,133.00	1.04T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	240.87	573.71B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	227.73	397.12B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	119.05	298.26B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	153.07	293.69B	54.66B	13.58B	16.05B	7.0171

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-25	Iniziato	RBC Capital Mkts	Sector Perform
2026-02-20	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	UBS	Neutral → Buy
2025-12-15	Aggiornamento	BofA Securities	Neutral → Buy
2025-12-12	Aggiornamento	Guggenheim	Neutral → Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-05	Downgrade	Daiwa Securities	Outperform → Neutral
2025-04-22	Iniziato	Cantor Fitzgerald	Neutral
2025-04-22	Iniziato	Piper Sandler	Overweight
2024-12-16	Aggiornamento	Jefferies	Hold → Buy
2024-12-10	Ripresa	BofA Securities	Neutral
2024-11-15	Iniziato	Wolfe Research	Peer Perform
2024-11-13	Aggiornamento	Daiwa Securities	Neutral → Outperform
2024-11-12	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-25	Downgrade	Citigroup	Buy → Neutral
2024-10-17	Iniziato	Bernstein	Mkt Perform
2024-07-29	Downgrade	Barclays	Overweight → Equal Weight
2024-03-11	Downgrade	Societe Generale	Buy → Hold
2024-02-06	Downgrade	Redburn Atlantic	Buy → Neutral
2024-01-03	Downgrade	BofA Securities	Buy → Neutral
2023-11-15	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-02	Downgrade	Daiwa Securities	Outperform → Neutral
2023-10-27	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-10-27	Aggiornamento	HSBC Securities	Reduce → Hold
2023-10-27	Downgrade	William Blair	Outperform → Mkt Perform
2023-10-20	Ripresa	UBS	Neutral
2023-07-14	Iniziato	HSBC Securities	Reduce
2023-07-10	Iniziato	SVB Securities	Market Perform
2023-06-28	Iniziato	Daiwa Securities	Outperform
2023-03-06	Iniziato	Jefferies	Hold
2023-01-17	Iniziato	Cantor Fitzgerald	Overweight
2022-11-18	Iniziato	Credit Suisse	Neutral
2022-10-10	Downgrade	Guggenheim	Buy → Neutral
2022-09-14	Downgrade	Berenberg	Buy → Hold
2022-06-03	Downgrade	Raymond James	Outperform → Mkt Perform
2022-04-06	Ripresa	Morgan Stanley	Underweight
2021-12-17	Iniziato	Goldman	Buy
2021-12-09	Ripresa	Wells Fargo	Equal Weight
2021-11-19	Iniziato	BMO Capital Markets	Outperform
2021-11-01	Downgrade	Argus	Buy → Hold
2021-07-27	Ripresa	Truist	Buy
2021-04-30	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-04-13	Aggiornamento	Truist	Hold → Buy
2020-11-16	Aggiornamento	Societe Generale	Hold → Buy
2020-11-10	Ripresa	Bernstein	Mkt Perform
2020-11-06	Downgrade	Gabelli & Co	Buy → Hold
2020-10-19	Aggiornamento	Guggenheim	Neutral → Buy
2020-09-29	Iniziato	Berenberg	Buy
2020-07-28	Iniziato	Raymond James	Outperform
2020-04-02	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-23	Downgrade	Societe Generale	Buy → Hold
2020-02-27	Iniziato	Barclays	Equal Weight
2020-01-06	Ripresa	Citigroup	Buy
2019-12-13	Aggiornamento	Argus	Hold → Buy
2019-11-22	Ripresa	Morgan Stanley	Equal-Weight
2019-10-17	Ripresa	BofA/Merrill	Buy
2019-08-14	Aggiornamento	Atlantic Equities	Neutral → Overweight
2019-05-28	Iniziato	Goldman	Buy
2019-05-20	Downgrade	Argus	Buy → Hold
2019-05-03	Aggiornamento	Barclays	Equal Weight → Overweight
2019-05-03	Ripresa	JP Morgan	Overweight
2019-01-15	Aggiornamento	Societe Generale	Sell → Buy
2018-10-22	Downgrade	Citigroup	Buy → Neutral

Mostra tutto

Bristol Myers Squibb Co Borsa (BMY) Ultime notizie

01:20 AM

Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? - TradingView

01:20 AM

11:00 AM

A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga

11:00 AM

07:50 AM

Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat

07:50 AM

05:55 AM

ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

05:55 AM

01:11 AM

Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance

01:11 AM

Jun 11, 2026

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

Jun 11, 2026

Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights

Jun 11, 2026

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters

Jun 11, 2026

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. - The Motley Fool

Jun 11, 2026

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga

Jun 11, 2026

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum

Jun 11, 2026

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Yahoo Finance

Jun 11, 2026

Jun 10, 2026

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Jun 10, 2026

Jun 09, 2026

Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance

Jun 09, 2026

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Jun 09, 2026

Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket - GuruFocus

Jun 09, 2026

BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Insider Monkey

Jun 09, 2026

Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign - Indian Pharma Post

Jun 09, 2026

Inside Bristol Myers’ AI-powered procurement overhaul - CFO Dive

Jun 09, 2026

Jun 08, 2026

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch

Jun 08, 2026

Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis - TradingKey

Jun 08, 2026

Disciplined Core Equity Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 08, 2026

Competitive approach better than restricting deals with China? - BioWorld News

Jun 08, 2026

Bristol Myers Squibb Tests CELMoD Research for Multiple Myeloma - Koran Manado

Jun 08, 2026

Mariska Hargitay Partners With Bristol Myers Squibb For Cancer Campaign - Koran Manado

Jun 08, 2026

Mariska Hargitay Honors Dad Mickey In Bristol Myers' Myeloma Campaign 06/08/2026 - MediaPost

Jun 08, 2026

Bristol Myers Squibb launches myeloma awareness campaign - Investing.com

Jun 08, 2026

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - 巴士的報

Jun 08, 2026

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease – Company AnnouncementFT.com - Financial Times

Jun 08, 2026

Bristol-Myers Squibb (BMY) Investor Outlook: Analyzing a Promising 10.14% Upside and 4.40% Dividend Yield - DirectorsTalk Interviews

Jun 08, 2026

Jun 06, 2026

Israel Englander Heavily Boosts Bristol Myers Squibb Position - HarianBasis.co

Jun 06, 2026

Jun 05, 2026

Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st

Jun 05, 2026

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance

Jun 05, 2026

Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 05, 2026

Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN

Jun 05, 2026

BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill

Jun 05, 2026

Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus

Jun 05, 2026

How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen - Yahoo Finance

Jun 05, 2026

Jun 04, 2026